Multiple Sclerosis Global Support Network News

"Your trusted source for the latest in MS news and information."

  • MS Info Hub
  • MS News

Multiple sclerosis: Oligodendrocytes from stem cells

A scientific collaboration between stem cell researchers of the Heinrich-Heine-University led by Prof. Küry (Dept. of Neurology) and by Prof. Adjaye (Institute for Stem...

Ocrevus (Ocrelizumab) Receives Market Approval in Switzerland

OCREVUS is the first and only approved treatment for people with primary progressive MS, a highly disabling form of MS An important new...

Mavenclad (Cladribine Tablets) Demonstrates Sustained Disease Control over 4 Years with...

CLARITY Extension data published in the MS Journal shows 75% of patients who received 2 annual short courses of Mavenclad (Cladribine Tablets) remained relapse free over 4 years  The majority of patients who...

Might Concussion in teenagers increases the risk of multiple sclerosis (MS)...

Concussion in teenagers increases the risk of multiple sclerosis (MS) in later life. However, there is no association with MS for concussion in younger...

Merck MAVENCLAD® (Cladribine) Receives Market Approval In Europe For Relapsing Multiple...

First oral short-course treatment for highly active relapsing multiple sclerosis (RMS) now approved in Europe Mavenclad has shown sustained clinical efficacy for up to...

IXICO expands Assessa PML Platform

IXICO plc (AIM: IXI), the digital technologies company serving neuroscience, announces an expansion of its pilot of the Assessa® PMLplatform which includes Biogen, a leading...

Biogen, AbbVie hit with Zinbryta safety action in EU as MS...

Biogen and AbbVie’s new multiple sclerosis drug Zinbryta faces fresh prescribing restrictions in Europe after regulators there reviewed liver injuries and one death in...

Novartis Marketing Application For AMG 334 Migraine (Erenumab) Med Accepted By...

Novartis today announced that the European Medicines Agency (EMA) has accepted its Marketing Authorization Application (MAA) for AMG 334 (erenumab) for the prevention of...

Alemtuzumab (Lemtrada) B-Cell Proliferation May Create New Autoimmunities in MS

In an analysis of previously unpublished phase III data, U.K. researchers reported a massive, rapid repopulation of a subset of B cells without effective...

Introducing Barts MS Charity – Lets Find Answers Together!

https://youtu.be/vTMxdN97TZ0 What is the objective of BartsMS Charity? To enable Barts-MS to undertake hard-to-fund, or to prime important, MS research projects. Our first key objective is to enable...

Subscribe To Our Newsletter